Related Experiment Videos
p21WAF1 mutations and human malignancies
M Shiohara1, K Koike, A Komiyama
1Department of Pediatrics, Shinshu University School of Medicine, Asahi, Matsumoto, Japan.
Leukemia & Lymphoma
|June 1, 1997
Summary
The p21WAF1 gene, a cyclin-dependent kinase inhibitor (CDKI), showed no structural alterations in human cancers. This suggests p21WAF1 may not play a significant role in cancer development or progression.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Cycle Regulation
Background:
- Cyclin-dependent kinase inhibitors (CDKIs) regulate cell cycle progression.
- p21WAF1 (CIP1/SDI1) is a CDKI induced by wild-type p53 and inhibits cyclin/CDK complexes and DNA polymerase.
- Cell cycle dysregulation is linked to cellular transformation and cancer.
Purpose of the Study:
- To investigate structural alterations in the p21WAF1 gene across various human malignancies.
- To determine the potential role of p21WAF1 in the onset and progression of human cancers.
Main Methods:
- Analysis of 471 primary tumor samples from 15 cancer types and 36 cell lines.
- Polymerase-chain reaction-single-strand conformation polymorphism (PCR-SSCP) to detect structural changes in the p21WAF1 gene coding region.
Main Results:
- No structural alterations were identified in the coding region of the p21WAF1 gene in the analyzed cancer samples.
- Many tumors analyzed possessed a normal p53 gene.
- Previous studies indicated p21WAF1 knockout mice did not exhibit increased cancer incidence, unlike p53 knockout mice.
Conclusions:
- The absence of p21WAF1 alterations in human malignancies suggests it may not be a key player in the initiation or progression of most human cancers.
- The tumor suppressor function of p53 likely involves other critical pathways beyond p21WAF1 activation.